These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28800166)

  • 1. Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.
    Bajaj G; Gupta M; Feng Y; Statkevich P; Roy A
    J Clin Pharmacol; 2017 Dec; 57(12):1527-1533. PubMed ID: 28800166
    [No Abstract]   [Full Text] [Related]  

  • 2. A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma.
    Wang R; Shao X; Zheng J; Saci A; Qian X; Pak I; Roy A; Bello A; Rizzo JI; Hosein F; Moss RA; Wind-Rotolo M; Feng Y
    Clin Pharmacol Ther; 2020 Apr; 107(4):978-987. PubMed ID: 31721173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction.
    Laroche A; Alarcon Chinchilla E; Bourgeault E; Doré MA
    J Cutan Med Surg; 2018; 22(6):627-629. PubMed ID: 29772919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.
    Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma.
    Nakamura Y; Fujino T; Kagamu H; Matsuya T; Teramoto Y; Asami Y; Yamamoto A
    JAMA Dermatol; 2017 Aug; 153(8):832-834. PubMed ID: 28492864
    [No Abstract]   [Full Text] [Related]  

  • 6. Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.
    Takahashi A; Kubo A; Mizuno S; Kasai K; Asai N; Yonezawa T; Kosaka K; Nishimura M; Tanaka H; Yokoe N; Tsuzuki T; Takami A; Yamaguchi E
    Intern Med; 2019 Mar; 58(6):827-831. PubMed ID: 30449777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab.
    Saito R; Sawada Y; Saito-Sasaki N; Yamamoto K; Yoshioka H; Ohmori S; Yoshioka M; Okada E; Nakamura M
    J Dermatol; 2018 Dec; 45(12):1452-1455. PubMed ID: 30204257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.
    van Bussel MTJ; Beijnen JH; Brandsma D
    BMC Cancer; 2019 May; 19(1):519. PubMed ID: 31146733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting marker for early progression in unresectable melanoma treated with nivolumab.
    Kondo T; Nomura M; Otsuka A; Nonomura Y; Kaku Y; Matsumoto S; Muto M
    Int J Clin Oncol; 2019 Mar; 24(3):323-327. PubMed ID: 30168088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
    Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
    J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.
    Ishida Y; Otsuka A; Tanaka H; Levesque MP; Dummer R; Kabashima K
    J Invest Dermatol; 2017 Nov; 137(11):2443-2444. PubMed ID: 28736235
    [No Abstract]   [Full Text] [Related]  

  • 12. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
    Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.
    Maeda T; Yoshino K; Nagai K; Oaku S; Kato M; Hiura A; Hata H
    Eur J Cancer; 2019 Jul; 115():13-16. PubMed ID: 31082687
    [No Abstract]   [Full Text] [Related]  

  • 14. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

  • 15. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.
    So H; Ikeguchi R; Kobayashi M; Suzuki M; Shimizu Y; Kitagawa K
    J Neurol Sci; 2019 Apr; 399():97-100. PubMed ID: 30798111
    [No Abstract]   [Full Text] [Related]  

  • 17. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
    Nakamura Y; Kitano S; Takahashi A; Tsutsumida A; Namikawa K; Tanese K; Abe T; Funakoshi T; Yamamoto N; Amagai M; Yamazaki N
    Oncotarget; 2016 Nov; 7(47):77404-77415. PubMed ID: 27764805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab in previously untreated melanoma without BRAF mutation.
    Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
    N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
    Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
    J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
    Anastasopoulou A; Papaxoinis G; Diamantopoulos P; Christofidou E; Benopoulou O; Stratigos A; Gogas H
    J Immunother; 2018 Apr; 41(3):164-167. PubMed ID: 29309291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.